Mr. Price is Executive Vice President, Chief Operating Officer and co-Founder of Promontory Therapeutics, and has been responsible for strategy, finance and operations across the company's activities since inception. He was named a 2022 Emerging Pharma Leader by Pharmaceutical Executive.
Mr. Price helped negotiate the original license for the company's PT-112 development program, and oversees the clinical and translational research and development. He is further responsible for the company's sub-license collaboration with SciClone Pharmaceuticals for greater China, its clinical trials collaboration jointly with Pfizer and Merck KGaA, Darmstadt, Germany, and its CRADA with the National Cancer Institute (NCI).
He previously held research and managerial roles in the NGO and non-profit sectors working in the US and Germany. He holds an AB from Princeton University, graduating summa cum laude and Phi Beta Kappa, and earned his MBA from Columbia Business School, where he was a Chazen Society Fellow in International Business.
Mr. Price helped negotiate the original license for the company's PT-112 development program, and oversees the clinical and translational research and development. He is further responsible for the company's sub-license collaboration with SciClone Pharmaceuticals for greater China, its clinical trials collaboration jointly with Pfizer and Merck KGaA, Darmstadt, Germany, and its CRADA with the National Cancer Institute (NCI).
He previously held research and managerial roles in the NGO and non-profit sectors working in the US and Germany. He holds an AB from Princeton University, graduating summa cum laude and Phi Beta Kappa, and earned his MBA from Columbia Business School, where he was a Chazen Society Fellow in International Business.
Speaking In
11:00 AM - 11:45 AM (EST)
Monday, February 6
Immuno-oncology therapies have revolutionized the treatment of many cancers over the last decade,…
South Broadway Ballroom
BIO DOUBLE HELIX SPONSORS
BIO HELIX SPONSORS
